This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asano, R. Articles by Kumagai, I. Search for Related Content PubMed PubMed Citation Articles by Asano, R. Articles by Kumagai, I.

Humanization of the Bispecific Epidermal Growth Factor Receptor x CD3 Diabody and Its Efficacy as a Potential Clinical Reagent

Authors' Affiliations: ¹ Department of Biomolecular Engineering, Graduate School of Engineering; ² Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine; and ³ Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan

Requests for reprints: Izumi Kumagai, Aoba 6-6-11-606, Aramaki-aza, Aoba-ku, Sendai 980-8579, Japan. Phone: 81-22-795-7274; Fax: 81-22-795-6164; E-mail: kmiz{at}kuma.che.tohoku.ac.jp.

Purpose: Bispecific antibodies (BsAb) have been exploited as both cancer immunodiagnostics and cancer therapeutics and show promise in clinical trials of cancer imaging and therapy. For development of BsAbs as clinical reagents, we have focused on construction of small recombinant BsAbs, called bispecific diabodies. Here, we constructed and characterized a humanized bispecific diabody.

Experimental Design: We have reported significant antitumor activity of an anti-epidermal growth factor receptor (EGFR) x anti-CD3 bispecific diabody (Ex3) in in vitro cytotoxicity assays and in vivo. We humanized the Ex3 diabody (hEx3) by grafting the complementarity-determining region and compared its biological properties with those of Ex3. We also tested its physiologic stability and ability to alter survival in xenografted mice.

Results: The final yield of hEx3 was 10 times that of Ex3, and refolded hEx3 and Ex3 showed identical binding profiles in EGFR-positive cell lines and EGFR-transfected Chinese hamster ovary cells. hEx3 showed dose-dependent cytotoxicity to EGFR-positive cell lines, which could be specifically inhibited by parental monoclonal antibody IgGs against EGFR or CD3 antigens. The heterodimeric structure was retained in PBS for 6 months, and growth inhibition was maintained after incubation under physiologic conditions. Coadministration of hEx3 with T-LAK cells and interleukin-2 prolonged the survival of nude mice with human colon carcinoma.

Conclusions: The humanized diabody hEx3 is an attractive molecule for cancer therapy and may provide important insights into the development of EGFR-based cancer-targeting reagents.

This article has been cited by other articles:

				R. Asano, Y. Sone, K. Ikoma, H. Hayashi, T. Nakanishi, M. Umetsu, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528 Protein Eng. Des. Sel., October 1, 2008; 21(10): 597 - 603. [Abstract] [Full Text] [PDF]

				T. Nakanishi, K. Tsumoto, A. Yokota, H. Kondo, and I. Kumagai Critical contribution of VH-VL interaction to reshaping of an antibody: The case of humanization of anti-lysozyme antibody, HyHEL-10 Protein Sci., February 1, 2008; 17(2): 261 - 270. [Abstract] [Full Text] [PDF]

				K. Makabe, T. Nakanishi, K. Tsumoto, Y. Tanaka, H. Kondo, M. Umetsu, Y. Sone, R. Asano, and I. Kumagai Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528 J. Biol. Chem., January 11, 2008; 283(2): 1156 - 1166. [Abstract] [Full Text] [PDF]

				R. Asano, Y. Watanabe, H. Kawaguchi, H. Fukazawa, T. Nakanishi, M. Umetsu, H. Hayashi, Y. Katayose, M. Unno, T. Kudo, et al. Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells J. Biol. Chem., September 21, 2007; 282(38): 27659 - 27665. [Abstract] [Full Text] [PDF]